This inventor holds 1 USPTO granted patent. Top assignees: Alexion Pharmaceuticals, Inc., National Institute of Health and Medical Research. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2026
Title: Innovations by Hugo Garcia in Ciliopathy Treatment
Introduction
Hugo Garcia is an accomplished inventor based in Maisons-Alfort, France. He has made significant contributions to the field of medicine, particularly in the treatment of diseases associated with ciliopathies. His innovative approaches have the potential to improve the lives of many individuals suffering from these complex conditions.
Latest Patents
Hugo Garcia holds a patent for "Methods for treating diseases associated with ciliopathies." This patent discloses methods of treating a ciliopathy-associated disease by administering an effective amount of a compound that targets at least one G-protein coupled receptor. Additionally, the patent outlines methods for identifying therapeutic agents for treating diseases related to ciliopathies. This includes providing an animal model system for testing potential therapeutic agents and comparing the measurable phenotypes of treated and untreated animals to identify effective treatments.
Career Highlights
Throughout his career, Hugo Garcia has worked with notable organizations such as Alexion Pharmaceuticals, Inc. and the National Institute of Health and Medical Research. His experience in these institutions has allowed him to develop and refine his innovative methods for treating ciliopathies.
Collaborations
Hugo has collaborated with esteemed colleagues, including Sophie Saunier and Luis Briseno-roa. These partnerships have contributed to the advancement of research in the field of ciliopathy treatment.
Conclusion
Hugo Garcia's work in developing methods for treating ciliopathy-associated diseases showcases his dedication to medical innovation. His contributions have the potential to lead to significant advancements in therapeutic approaches for these challenging conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile